Free Trial

Uranium Royalty (TSE:URC) Hits New 52-Week High - Time to Buy?

Uranium Royalty logo with Energy background

Shares of Uranium Royalty Corp. (TSE:URC - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as C$4.51 and last traded at C$4.23, with a volume of 450069 shares. The stock had previously closed at C$3.67.

Uranium Royalty Trading Up 2.2%

The firm has a 50-day moving average of C$3.30 and a two-hundred day moving average of C$3.00. The firm has a market capitalization of C$574.75 million, a PE ratio of 80.67 and a beta of 1.69.

About Uranium Royalty

(Get Free Report)

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment, the investment in a portfolio of uranium interests.

Recommended Stories

Should You Invest $1,000 in Uranium Royalty Right Now?

Before you consider Uranium Royalty, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Uranium Royalty wasn't on the list.

While Uranium Royalty currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines